Floatz logo

Alpha-Interferon

Cough

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Cough cohort.

Asset / SponsorPhaseRating
Thalidomide
Johns Hopkins University
Phase 3BB
Gefapixant
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2B
SUPLATAST TOSYLATE
Melius Pharma AB
Phase 2CCC
Capsaicin
University of Florida
Phase 1/2CCC
Orvepitant
Nerre Therapeutics Ltd.
Phase 2CC
Azithromycin
Insel Gruppe AG, University Hospital Bern
N/AD

Same molecule, other indications

Alpha-Interferon is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal cell carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
kidney cancerDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →